Q-omics provides the consensus-scored CFB profile across patient tissues and cancer cell-line models. CFB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CFB is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CFB RNA expression shows 17,374 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where CFB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFB survival associations across molecular data types. CFB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFB RNA expression–survival associations across cancer types. High CFB expression shows unfavorable associations in LGG and LUSC, but favorable associations in MESO, SKCM, BRCA and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CFB RNA expression.
This table summarizes CFB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CFB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFB shows lower tumor expression in KICH and higher tumor expression in COAD, THCA, KIRC, LUAD and BRCA. The KICH box plot shows higher CFB RNA expression in normal versus tumor tissue (log2 FC = −2.705, t-test p < 0.001).
This table shows molecular features associated with CFB in patient tissues and cancer cell lines. In patient samples, CFB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
